SAVING LIVES
MEDICINE REDEFINED
Innovative, accessible, and life-saving treatments to
redefine care for patients with unmet medical needs.
Engineering the next generation of medicine
AGEM Bio is a therapeutic biotechnology company developing next-generation cell therapies using a proprietary, non-viral genetic delivery platform. Our technology enables the precise engineering of mesenchymal stem cells (MSCs) to deliver life-saving therapeutics, pioneering the MSC 2.0 era of cell therapy.
Our platform is broadly applicable across multiple disease areas, including oncology and regenerative medicine. Our flagship program, AGEM-102, is currently in development for a range of difficult-to-treat solid tumours.
Mesenchymal stem cells are at the forefront of modern cell therapy. By harnessing their intrinsic biological properties and functionalising them for specific disease indications, AGEM Bio aims to unlock new therapeutic possibilities for conditions that remain inadequately treated today.
Technology & Pipelines
We pride ourselves on our unique MSC 2.0 technology, which harnesses the power of our proprietary non-viral gene delivery platform to augment the capabilities of mesenchymal stem cells.
Latest News
AGeM Bio awarded NMRC Clinical Trial Grant for Phase 1 Study of AGeM-102
AGeM Bio is proud to announce a major milestone in our mission to develop innovative therapies for patients with limited treatment options. Dr. Vincent Nga ...
AGeM Bio secures key Singapore patent for Non-Viral Stem Cell Engineering platform
AGeM Bio is pleased to announce that we have been granted a Singapore national phase patent for our proprietary invention: “Non-Viral Modification of Mesenchymal Stem Cells” ...
AGeM Bio named recipient of Thermo Fisher Scientific’s BioXcelerate Award to Advance MSC-based Clinical Trial
AGeM Bio is proud to share that we have been chosen for the prestigious BioXcelerate Award by Thermo Fisher Scientific ...